✨ Free AI Report
Innoviva, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Innoviva, Inc.
Research Preview

Innoviva, Inc.: Business Overview, Financials & Competitive Analysis

Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic...

Analyst-debate audio for Innoviva, Inc.

AskCyborg analysts argue the bull and bear cases for Innoviva, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Innoviva, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Dual-engine growth model combining stable royalty income with high-growth infectious disease and critical care platform drives...

Read the full analyst-debate transcript →
Industry Biopharmaceutical Manufacturing & Specialty Therapeutics
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 15, 2026
AI-Verified Research
30+ Page Report

Get the Latest Innoviva, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Innoviva, Inc. Overview

Pro stress-test →

Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets. The company demonstrated strength across all areas in 2025 with 15% revenue growth to over $400 million, stable royalty cash flow, and IST generated 47% year-over-year U.S. sales growth to $119 million.

Strategic Profile

Pro stress-test →

Innoviva's royalties portfolio centers on respiratory assets partnered with Glaxo Group Limited (GSK), providing ongoing revenue from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA® sales. Through its specialty therapeutics division, Innoviva commercializes critical care and infectious disease products including GIAPREZA, XERAVA, XACDURO, and ZEVTERA, with recent FDA approval of NUZOLVENCE for uncomplicated urogenital gonorrhea.

Competitive Landscape

Pro stress-test →

Innoviva competes in respiratory therapy market (RELVAR/BREO, ANORO ELLIPTA), critical care vasoconstriction (GIAPREZA vs other vasopressors), and infectious disease treatment (XERAVA, XACDURO, ZEVTERA, NUZOLVENCE) against established pharmaceutical companies and specialty biotech firms.

Industry Context

Innoviva, Inc. operates in Biopharmaceutical Manufacturing & Specialty Therapeutics.

Key facts

Founded: 1996 · Headquarters: Burlingame, California, United States · Employees: 127 · Revenue: $411.3M · Market cap: $1.8B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Innoviva, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Innoviva, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

BREO ELLIPTA / ANORO ELLIPTARespiratory combination therapies in same product class→Other vasopressors and antibioticsCompetitive products in critical care and infectious disease→

Compare Innoviva, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Innoviva, Inc. operates in Biopharmaceutical Manufacturing & Specialty Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical Manufacturing & Specialty Therapeutics research →
NEW · MCP server

Ask your AI assistant about Innoviva, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Innoviva, Inc. and its top competitor on Cyborg Score”
“What did Innoviva, Inc. do this quarter?”
“Is Innoviva, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Innoviva, Inc. do?+
Innoviva is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic...
What is Innoviva, Inc.'s Cyborg Score?+
Innoviva, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Innoviva, Inc.'s main competitors?+
Named competitors include BREO ELLIPTA / ANORO ELLIPTA, Other vasopressors and antibiotics. The full competitive landscape is in the AskCyborg report.
How can I get the full Innoviva, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Innoviva, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Innoviva, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9National Bank of Pakistan9RENK Group AG9Lumentum Holdings Inc.9First Abu Dhabi Bank9The Travelers Companies, Inc.9BAE Systems plc9Arista Networks9KLA Corporation9Hermès International S.A.8Enerjisa Enerji A.Ş.8Emirates Central Cooling Systems Corporation8WALLIX Group8StealthGas Inc.8SofWave Medical Ltd.8Himalaya Shipping Ltd.8Bannerman Energy Ltd8Sembcorp Salalah Power & Water Company8MilDef Group